<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951453</url>
  </required_header>
  <id_info>
    <org_study_id>H-21004729</org_study_id>
    <nct_id>NCT04951453</nct_id>
  </id_info>
  <brief_title>Systemic Nitrosative/Oxidative Stress in Patients With Acute Brain Injury</brief_title>
  <acronym>NOX</acronym>
  <official_title>Systemic Nitrosative/Oxidative Stress in Patients With Acute Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute brain injury due to traumatic brain injury (TBI), intracerebral haemorrhage (ICH), and&#xD;
      aneurysmal subarachnoid haemorrhage (SAH) carries a high morbidity and mortality, in part due&#xD;
      to the development of secondary brain injury. The mechanisms behind secondary brain injury&#xD;
      are incompletely understood, but oxidative/nitrosative stress and disturbances in the&#xD;
      metabolism of the vasodilator nitric oxide (NO) are believed to be involved. The aim of the&#xD;
      present study is to characterise systemic changes in markers of oxidative/nitrosative stress&#xD;
      and NO metabolism in the early phase after acute brain injury, and to examine their&#xD;
      relationship to clinical course, neurological outcome, and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Acute brain injury due to traumatic brain injury (TBI), intracerebral haemorrhage (ICH), and&#xD;
      aneurysmal subarachnoid haemorrhage (SAH) is a major cause of mortality and permanent&#xD;
      disability worldwide. Irrespective of its aetiology, acute brain injury is associated with a&#xD;
      widespread activation of cellular and biochemical processes which can aggravate the damage&#xD;
      after the primary injury - this is termed secondary brain injury.&#xD;
&#xD;
      Nitric oxide (NO) is a potent endogenous vasodilator produced from arginine by the enzyme&#xD;
      nitric oxide synthase (NOS), which exists in three isoforms: endothelial, neuronal, and&#xD;
      inducible NOS (eNOS, nNOS and iNOS). In conditions of inflammation and oxidative stress (e.g.&#xD;
      in acute brain injury), free radicals may react with NO to form peroxynitrite (ONOO-), which&#xD;
      is highly reactive and can directly damage biological macromolecules such as lipids and&#xD;
      proteins. This phenomenon, i.e. an increased production of reactive nitrogen species&#xD;
      potentially leading to cellular damage, is termed nitrosative stress.&#xD;
&#xD;
      It is widely believed that oxidative/nitrosative stress and associated disturbances in the&#xD;
      metabolism of NO are involved in the development of secondary brain injury, but the exact&#xD;
      role of these mechanisms remains incompletely understood. While some authors believe that NOS&#xD;
      dysfunction and a resultant low NO bioavailability is an important cause of secondary brain&#xD;
      injury, others argue that an overproduction of NO mediated by iNOS is maladaptive response&#xD;
      leading to aggravated tissue injury due to nitrosative stress.&#xD;
&#xD;
      The investigators hypothesise that acute brain injury is associated with an immediate&#xD;
      elevation in circulating biomarkers of oxidative stress and a reduction in the&#xD;
      bioavailability of NO due to formation of peroxynitrite (nitrosative stress), and that this&#xD;
      represents an important mechanism behind the development of secondary brain injury. This&#xD;
      decrease in NO availability could contribute to a vicious cycle in which a resulting increase&#xD;
      in microvascular resistance, cerebral hypoperfusion, and brain tissue hypoxia further&#xD;
      increases free radical production. However, it is further hypothesised that the initial&#xD;
      decrease in NO availability is followed by an iNOS-mediated increase in NO metabolites in the&#xD;
      subsequent days after injury. The present explorative study will attempt to characterise&#xD;
      these changes and their role in patients with acute brain injury.&#xD;
&#xD;
      HYPOTHESES:&#xD;
&#xD;
        1. Patients will have the highest levels of oxidative/nitrosative stress markers and lowest&#xD;
           levels of NO metabolites immediately after ictus, with a progressive reduction in&#xD;
           oxidative/nitrosative stress markers and increase in NO metabolites over the subsequent&#xD;
           days.&#xD;
&#xD;
        2. The degree of oxidative/nitrosative stress will be associated with an unfavourable&#xD;
           clinical course (e.g., episodes of neuroworsening), poor neurological outcome, and&#xD;
           death.&#xD;
&#xD;
        3. Patients with a higher disease severity (e.g., a higher World Federation of Neurological&#xD;
           Surgeons Score for patients with SAH) will have a greater degree of&#xD;
           oxidative/nitrosative stress compared to patients with a lower disease severity.&#xD;
&#xD;
        4. The degree of oxidative/nitrosative stress will be associated with the degree of&#xD;
           biomarker-determined neurovascular unit injury.&#xD;
&#xD;
        5. The degree of oxidative/nitrosative stress will be associated with evidence of systemic&#xD;
           organ dysfunction.&#xD;
&#xD;
        6. The degree of oxidative/nitrosative stress and relative NO-depletion is associated with&#xD;
           brain tissue hypoxia, brain metabolic crisis, and cortical spreading depolarisations (in&#xD;
           a subset of patients undergoing multimodal neuromonitoring).&#xD;
&#xD;
      METHODS:&#xD;
&#xD;
      The study is a single-center, prospective, explorative, observational study, which will&#xD;
      include 50 patients with SAH, 50 patients with ICH, and 50 patients with TBI admitted to the&#xD;
      Neurointensive Care Unit (NICU) at Rigshospitalet, Copenhagen. Patient inclusion will&#xD;
      continue until the planned number of patients have been enrolled, or until the 1st of May&#xD;
      2023, at which point inclusion will be halted and data will be analysed irrespective of the&#xD;
      number of included patients.&#xD;
&#xD;
      Arterial blood samples will be collected at 3 time points: day 0-2 (early), day 3-5&#xD;
      (intermediate) and day 6-8 (late) after admission. If no arterial catheter is available,&#xD;
      central venous or peripheral venous samples may be drawn as an alternative. Blood samples&#xD;
      will only be collected during admission to the NICU and/or intermediate care unit, and sample&#xD;
      collection will be halted in case of discharge to another department.&#xD;
&#xD;
      Demographical, clinical and paraclinical data will be obtained from each patients' electronic&#xD;
      medical records. Data from multimodal neuromonitoring (i.e., intracranial pressure, brain&#xD;
      tissue oxygenation, cerebral microdialysis, and/or electrocorticography) will be collected&#xD;
      continuously along with physiological parameters when available. Neurological outcome (as&#xD;
      determined by the modified Rankin Scale) will be determined at 6 months in connection with an&#xD;
      outpatient follow-up visit at the hospital or through telephone interviews.&#xD;
&#xD;
      BIOCHEMICAL ANALYSES:&#xD;
&#xD;
      Blood samples will be analysed for the following markers of oxidative stress: the ascorbate&#xD;
      radical, lipid hydroperoxides, myeloperoxidase, and the antioxidants glutathione,&#xD;
      α/γ-tocopherol, α/β-carotene, retinol and lycopene.&#xD;
&#xD;
      The following NO metabolites will be determined: total plasma NO concentration (nitrate&#xD;
      (NO3-) + nitrite (NO2-) + S-nitrosothiols (RSNO)) and total red blood cell bound NO (nitrite&#xD;
      (NO2-) + nitrosyl haemoglobin (HbNO) + S-nitrosohaemoglobin (HbSNO)). In addition,&#xD;
      3-nitrotyrosine will be determined as a surrogate marker for peroxynitrite.&#xD;
&#xD;
      The following biomarkers of neurovascular unit injury will be determined: S100ß, glial&#xD;
      fibrillary acidic protein, neuron-specific enolase, ubiquitin carboxy-terminal hydrolase L1,&#xD;
      neurofilament light-chain and total tau.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome (modified Rankin scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Neurological outcome as assessed using the modified Rankin Scale, which measures the degree of disability on a scale from 0 to 6 (higher score indicates a worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroworsening</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Neuroworsening as defined by Morris et al. [1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Cerebral Ischaemia (DCI)</measure>
    <time_frame>Within 14 days</time_frame>
    <description>DCI as defined by Vergouwen et al. [2] (in patients with SAH)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Levels of brain injury biomarkers</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Concentrations of the brain injury biomarkers S100ß (μg/L), glial fibrillary acidic protein (pg/mL), neuron-specific enolase (μg/L), ubiquitin carboxy-terminal hydrolase L1 (pg/mL), neurofilament light-chain (pg/mL) and total tau (pg/mL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiographic vasospasm</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Angiographic vasospasm (in patients with SAH)</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay</measure>
    <time_frame>During hospitalisation</time_frame>
    <description>Length of stay in the intensive care unit (ICU) and in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Systemic organ dysfunction</measure>
    <time_frame>During ICU stay</time_frame>
    <description>Systemic organ dysfunction as assessed by the Sequential Organ Failure Assessment (SOFA)-score during stay in the ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain tissue hypoxia</measure>
    <time_frame>During ICU stay</time_frame>
    <description>Brain tissue hypoxia (defined as a brain tissue oxygen tension of &lt;20 mmHg) as assessed by invasive brain tissue oxygen monitoring (Integra Licox®) in patients undergoing multimodal neuromonitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain metabolic crisis</measure>
    <time_frame>During ICU stay</time_frame>
    <description>Brain metabolic crisis (defined as a lactate/pyruvate ratio &gt;40 with a brain glucose concentration ≤0.7 mmol/L) as assessed by cerebral microdialysis in patients undergoing multimodal neuromonitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Cortical spreading depolarisations</measure>
    <time_frame>During ICU stay</time_frame>
    <description>The frequency (occurrence) of cortical spreading depolarisations as assessed by electrocorticography in patients undergoing multimodal neuromonitoring.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Aneurysmal subarachnoid haemorrhage</arm_group_label>
    <description>Patients with SAH (see eligibility criteria below). Planned enrollment: 50 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracerebral haemorrhage</arm_group_label>
    <description>Patients with ICH (see eligibility criteria below). Planned enrollment: 50 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
    <description>Patients with TBI (see eligibility criteria below). Planned enrollment: 50 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None (observational)</intervention_name>
    <description>None (observational)</description>
    <arm_group_label>Aneurysmal subarachnoid haemorrhage</arm_group_label>
    <arm_group_label>Intracerebral haemorrhage</arm_group_label>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (whole blood, serum, plasma, and red blood cells)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute brain injury (SAH, ICH or TBI) admitted to the NICU at Rigshospitalet -&#xD;
        see detailed inclusion and exclusion criteria above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission to the Neurointensive Care Unit (NICU) at Rigshospitalet&#xD;
&#xD;
          -  Diagnosis of TBI, spontaneous ICH or aneurysmal SAH&#xD;
&#xD;
          -  Initiation of blood sampling possible within 3 days after ictus&#xD;
&#xD;
          -  Expected length of stay in the NICU and/or intermediate care unit of ≥48 hours&#xD;
&#xD;
          -  Closest relatives understand written and spoken Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain death before inclusion&#xD;
&#xD;
          -  Expected death within 24 hours&#xD;
&#xD;
          -  ICH secondary to other causes (e.g., a tumour or arteriovenous malformation)&#xD;
&#xD;
          -  SAH secondary to other causes (e.g., a mycotic aneurysm or arteriovenous malformation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Lund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anton Lund, MD</last_name>
    <phone>+45 35 45 59 81</phone>
    <email>anton.lund@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirsten Møller, MD, DMSc</last_name>
    <phone>+45 35 45 16 16</phone>
    <email>kirsten.moeller.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Lund, MD</last_name>
      <phone>+45 35 45 59 81</phone>
      <email>anton.lund@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kirsten Møller, MD, DMSc</last_name>
      <phone>+45 35 45 16 16</phone>
      <email>kirsten.moeller.01@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Anton Lund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Morris GF, Juul N, Marshall SB, Benedict B, Marshall LF. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial. Neurosurgery. 1998 Dec;43(6):1369-72; discussion 1372-4.</citation>
    <PMID>9848851</PMID>
  </reference>
  <reference>
    <citation>Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YB. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010 Oct;41(10):2391-5. doi: 10.1161/STROKEAHA.110.589275. Epub 2010 Aug 26.</citation>
    <PMID>20798370</PMID>
  </reference>
  <reference>
    <citation>Stocchetti N, Taccone FS, Citerio G, Pepe PE, Le Roux PD, Oddo M, Polderman KH, Stevens RD, Barsan W, Maas AI, Meyfroidt G, Bell MJ, Silbergleit R, Vespa PM, Faden AI, Helbok R, Tisherman S, Zanier ER, Valenzuela T, Wendon J, Menon DK, Vincent JL. Neuroprotection in acute brain injury: an up-to-date review. Crit Care. 2015 Apr 21;19:186. doi: 10.1186/s13054-015-0887-8. Review.</citation>
    <PMID>25896893</PMID>
  </reference>
  <reference>
    <citation>Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007 Jul;99(1):4-9. Review.</citation>
    <PMID>17573392</PMID>
  </reference>
  <reference>
    <citation>Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. Review.</citation>
    <PMID>17237348</PMID>
  </reference>
  <reference>
    <citation>Garry PS, Ezra M, Rowland MJ, Westbrook J, Pattinson KT. The role of the nitric oxide pathway in brain injury and its treatment--from bench to bedside. Exp Neurol. 2015 Jan;263:235-43. doi: 10.1016/j.expneurol.2014.10.017. Epub 2014 Oct 29. Review.</citation>
    <PMID>25447937</PMID>
  </reference>
  <reference>
    <citation>Toda N, Ayajiki K, Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol Rev. 2009 Mar;61(1):62-97. doi: 10.1124/pr.108.000547. Epub 2009 Mar 16. Review.</citation>
    <PMID>19293146</PMID>
  </reference>
  <reference>
    <citation>Cherian L, Goodman JC, Robertson CS. Brain nitric oxide changes after controlled cortical impact injury in rats. J Neurophysiol. 2000 Apr;83(4):2171-8.</citation>
    <PMID>10758126</PMID>
  </reference>
  <reference>
    <citation>Sehba FA, Schwartz AY, Chereshnev I, Bederson JB. Acute decrease in cerebral nitric oxide levels after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2000 Mar;20(3):604-11.</citation>
    <PMID>10724124</PMID>
  </reference>
  <reference>
    <citation>Sehba FA, Bederson JB. Nitric oxide in early brain injury after subarachnoid hemorrhage. Acta Neurochir Suppl. 2011;110(Pt 1):99-103. doi: 10.1007/978-3-7091-0353-1_18. Review.</citation>
    <PMID>21116923</PMID>
  </reference>
  <reference>
    <citation>Sobey CG, Faraci FM. Subarachnoid haemorrhage: what happens to the cerebral arteries? Clin Exp Pharmacol Physiol. 1998 Nov;25(11):867-76. Review.</citation>
    <PMID>9807657</PMID>
  </reference>
  <reference>
    <citation>Sehba FA, Chereshnev I, Maayani S, Friedrich V Jr, Bederson JB. Nitric oxide synthase in acute alteration of nitric oxide levels after subarachnoid hemorrhage. Neurosurgery. 2004 Sep;55(3):671-7; discussion 677-8.</citation>
    <PMID>15335435</PMID>
  </reference>
  <reference>
    <citation>Hino A, Tokuyama Y, Weir B, Takeda J, Yano H, Bell GI, Macdonald RL. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery. 1996 Sep;39(3):562-7; discussion 567-8.</citation>
    <PMID>8875487</PMID>
  </reference>
  <reference>
    <citation>Jung CS, Oldfield EH, Harvey-White J, Espey MG, Zimmermann M, Seifert V, Pluta RM. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2007 Nov;107(5):945-50.</citation>
    <PMID>17977265</PMID>
  </reference>
  <reference>
    <citation>Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta Neurochir Suppl. 2008;104:139-47. Review.</citation>
    <PMID>18456999</PMID>
  </reference>
  <reference>
    <citation>Bailey DM, Taudorf S, Berg RM, Lundby C, McEneny J, Young IS, Evans KA, James PE, Shore A, Hullin DA, McCord JM, Pedersen BK, Möller K. Increased cerebral output of free radicals during hypoxia: implications for acute mountain sickness? Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1283-92. doi: 10.1152/ajpregu.00366.2009. Epub 2009 Sep 2.</citation>
    <PMID>19726713</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anton Lund</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Nitrosative Stress</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Acute Brain Injury</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Secondary Brain Injury</keyword>
  <keyword>Neuromonitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from each individual participant will be available after publication of planned manuscripts, with a valid reason, and after signing a data processing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The approved study protocol will be available upon request until publication of the study results.</ipd_time_frame>
    <ipd_access_criteria>Valid reason and contact with author.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

